CalciMedica Future Growth
Future criteria checks 0/6
CalciMedica is forecast to grow earnings and revenue by 20.3% and 75.7% per annum respectively while EPS is expected to grow by 49.3% per annum.
Key information
20.3%
Earnings growth rate
49.3%
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | 75.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 24 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3 | -34 | -43 | -27 | 3 |
| 12/31/2025 | N/A | -36 | -35 | -21 | 3 |
| 12/31/2024 | N/A | -26 | -31 | -19 | 3 |
| 12/31/2023 | N/A | -34 | -26 | -26 | N/A |
| 9/30/2023 | N/A | -30 | -26 | -26 | N/A |
| 6/30/2023 | N/A | -28 | -24 | -23 | N/A |
| 3/31/2023 | N/A | -25 | -13 | -13 | N/A |
| 12/31/2022 | N/A | -9 | -12 | -12 | N/A |
| 9/30/2022 | N/A | -14 | -11 | -11 | N/A |
| 12/31/2021 | N/A | -24 | -21 | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CALC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CALC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CALC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CALC is forecast to have no revenue next year.
High Growth Revenue: CALC is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CALC's Return on Equity is forecast to be high in 3 years time